Patents by Inventor Timothy James Morley

Timothy James Morley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE
    Publication number: 20220169594
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1° 2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Application
    Filed: August 10, 2021
    Publication date: June 2, 2022
    Applicant: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
    Patent number: 11117855
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: September 14, 2021
    Assignee: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
    Patent number: 11072577
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: July 27, 2021
    Assignee: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE
    Publication number: 20210188761
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 24, 2021
    Applicant: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE
    Publication number: 20210163398
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 3, 2021
    Applicant: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
    Patent number: 10988436
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: April 27, 2021
    Assignee: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
    Patent number: 10947184
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: March 16, 2021
    Assignee: Orphalan S.A.
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE
    Publication number: 20200392068
    Abstract: The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2? and Raman shifts 943, 1173, 1527 and 1612±5 cm?1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
    Type: Application
    Filed: June 30, 2020
    Publication date: December 17, 2020
    Applicant: GMP-ORPHAN SA
    Inventors: Timothy James Morley, Ronnie Maxwell Lawrence, Naseem Amin
  • Fused indole derivatives
    Patent number: 6610685
    Abstract: The present invention is a chemical compound of formula (I) or a pharmaceutically acceptable salt, solvate and ester thereof, wherein R1 to R4 and n are as defined in the specification. A compound of formula 1 is useful as a pharmaceutical composition for the treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes, obesity and sleep apnoea.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: August 26, 2003
    Assignees: Hoffmann-La Roche Inc., Vernalis Research Limited
    Inventors: Jonathan Mark Bentley, Michael John Bickerdike, Paul Hebeisen, Guy Anthony Kennett, Sean Lightowler, Patrizio Mattei, Jacques Mizrahi, Timothy James Morley, Jean-Marc Plancher, Hans Richter, Stephan Roever, Sven Taylor, Steven Paul Vickers
  • Novel indole derivatives
    Publication number: 20020160997
    Abstract: The present invention is a chemical compound of formula (I) 1
    Type: Application
    Filed: December 14, 2001
    Publication date: October 31, 2002
    Inventors: Jonathan Mark Bentley, Michael John Bickerdike, Paul Hebeisen, Guy Anthony Kennett, Sean Lightowler, Patrizio Mattei, Jacques Mizrahi, Timothy James Morley, Jean-Marc Plancher, Hans Richter, Stephan Roever, Sven Taylor, Steven Paul Vickers